Research Topics
| D GurwitzSummaryAffiliation: Tel Aviv University Country: Israel Publications
| Collaborators
|
Detail Information
Publications
[Pharmacogenetics: towards personalized medicine]David Gurwitz
Department of Human Genetics and Molecular Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Harefuah 144:711-6, 750. 2005..Education of health professionals in pharmacogenetics as part of their pharmacology curricula, and explaining its potential to the general public, would be indispensable for the success of personalized medicine...
A call for the creation of personalized medicine databasesDavid Gurwitz
Department of Human Genetics and Molecular Medicine, Sackler Faculty of Medicine, Tel Aviv University, Israel
Nat Rev Drug Discov 5:23-6. 2006..Here, we discuss the rationale for such personalized medicine databases, and the key practical and ethical issues that need to be addressed in their establishment...
'Drug reactions, enzymes, and biochemical genetics': 50 years laterDavid Gurwitz
Pharmacogenomics 8:1479-84. 2007
Ancestry in translational genomic medicine: handle with careDavid Gurwitz
Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
Genome Med 1:24. 2009..Translational genomic medicine will allow for individualized clinical decision making - doing away with the use of race, ethnicity or ancestry as a proxy...
Do endogenous cannabinoids contribute to HIV-mediated immune failure?D Gurwitz
National Laboratory for the Genetics of Israeli Populations, Sackler Faculty of Medicine, Tel Aviv University, Israel
Mol Med Today 4:196-200. 1998..Here, we propose the hypothesis that endogenous cannabinoids, derived mostly from macrophages, might participate in the general failure of the immune system in HIV-infected individuals...
Pharmacogenetics education: 10 years of experience at Tel Aviv UniversityDavid Gurwitz
Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Pharmacogenomics 11:647-9. 2010..I share here my pharmacogenetics teaching experience over the past decade and look forward to 2020 when - hopefully - the use of pharmacogenetics tools will have become more established in routine clinical care...
Pharmacogenomics: the importance of accurate phenotypesDavid Gurwitz
Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 69978 Israel
Pharmacogenomics 11:469-70. 2010..Biobanks created with personalized medicine research in mind should, when possible, have access to donors' clinical data, including detailed disease- and drug-response phenotypes...
Personal genomics services: whose genomes?David Gurwitz
Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Eur J Hum Genet 17:883-9. 2009..We also point out some specific steps, along the trustee model, that providers of DTC personal genomics services as well as regulators and policy makers could consider for addressing some of the concerns raised below...
Personalized participatory medicine: sharing knowledge and uncertaintyDavid Gurwitz
Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
Genome Med 3:69. 2011..This is illustrated by a case study on treatment choices of breast cancer patients following genotyping for CYP2D6, recently published in Genome Medicine.See research article: http://genomemedicine.com/content/3/10/64...
Personalized medicine Europe: health, genes and society: Tel-Aviv University, Tel-Aviv, Israel, June 19-21, 2005David Gurwitz
Department of Human Genetics and Molecular Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Eur J Hum Genet 14:376-80. 2006
Personalized psychiatry: a realistic goalDavid Gurwitz
Department of Human Genetics and Molecular Medicine, Sackler Faculty of Medicine, Tel Aviv University, Israel
Pharmacogenomics 5:213-7. 2004..With the correct focus, realization of some benefits of genetic patient profiling for psychiatric pharmacotherapy might be near, and in due course, lead the way for true personalized psychiatry...
Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of educationD Gurwitz
Department of Human Genetics and Molecular Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Pharmacogenomics J 5:221-5. 2005..We hope that this call would be listened to, and soon followed by beneficial action, ultimately leading to enhanced implementation of personalized medicine into core medical education and practice...
Education: Teaching pharmacogenomics to prepare future physicians and researchers for personalized medicineDavid Gurwitz
Department of Human Genetics and Molecular Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
Trends Pharmacol Sci 24:122-5. 2003....
Quantitative measurements of mouse brain thrombin-like and thrombin inhibition activitiesO Beilin
Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978 Israel
Neuroreport 12:2347-51. 2001..2 mU thrombin/mg brain tissue. The present study offers a simple and reliable method for measuring total thrombin inhibitory activity in brain...
Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and SpainDavid Gurwitz
Department of Human Molecular Genetics and Biochemistry, Tel Aviv University, Israel
Eur J Hum Genet 17:991-8. 2009..Further data are needed for determining the cost-effectiveness of routine TPMT testing...
Human lymphoblastoid cell line panels: novel tools for assessing shared drug pathwaysAyelet Morag
Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
Pharmacogenomics 11:327-40. 2010..We present a novel in vitro method for distinguishing shared versus distinct drug pathways based on comparative cell growth inhibition profiles across a small panel of human lymphoblastoid cell lines (LCLs) from individual donors...
Ethnicity-related polymorphisms and haplotypes in the human ABCB1 geneChava Kimchi-Sarfaty
National Institutes of Health, Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892 4254, USA
Pharmacogenomics 8:29-39. 2007..Three SNPs, 1236C-->T, 2677G-->T and 3435C-->T, have been repeatedly shown to predict changes in the function of P-gp. The frequencies with which these polymorphisms exist in a population have also been shown to be ethnically related...
Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in EuropeM Elske van den Akker-van Marle
TNO (Netherlands Organization for Applied Scientific Research, Quality of Life, Leiden/Delft, The Netherlands
Pharmacogenomics 7:783-92. 2006..Our analysis indicates that TPMT genotyping should be seriously considered as an integral part of healthcare prior to the initiation of therapy with thiopurine drugs...
MtDNA evidence for a genetic bottleneck in the early history of the Ashkenazi Jewish populationDoron M Behar
Bruce Rappaport Faculty of Medicine and Research Institute, Technion and Rambam Medical Center, Haifa, Israel
Eur J Hum Genet 12:355-64. 2004..A genetic bottleneck followed by the recent phenomenon of rapid population growth are likely to have produced the conditions that led to the high frequency of many genetic disease alleles in the Ashkenazi population...
A human genome diversity cell line panelHoward M Cann
Science 296:261-2. 2002
Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysisDavid Gurwitz
J Natl Cancer Inst 100:1331; author reply 1332-4. 2008
Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patientsKenji Nakai
Iwate Medical University, Department of Laboratory Medicine, Morioka 020 8505, Japan
Pharmacogenomics 8:713-9. 2007....
Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharingRuss B Altman
Stanford University, Department of Genetics and Bioengineering, Clark S172, Stanford, CA 94305-5444, USA
Pharmacogenomics 8:519. 2007
Primum non nocere: adverse drug events must be taken seriouslyDavid Gurwitz
Pharmacogenomics 8:311-4. 2007
Personalized medicine: decades away?Jeantine E Lunshof
VU University Medical Center, Section Community Genetics, Department of Clinical Genetics and Human Genetics, EMGO Institute, PO Box 7057, 1007 MB Amsterdam, The Netherlands
Pharmacogenomics 7:237-41. 2006
From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the communityFelix W Frueh
Stepoutside Consulting, LLC, Gaithersburg, MD 20878, USA
Pharmacogenomics 5:571-9. 2004..To effectively move pharmacogenetics into everyday medicine, it is therefore imperative for scientists and teachers in the field to take on the challenge of disseminating pharmacogenetic insights to a broader audience...
Ethnic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) genotypes in Japanese and Israeli populationsKenji Nakai
Department of Laboratory Medicine, Iwate Medical University, Morioka 020 8505, Japan
Life Sci 78:107-11. 2005..85/0.15) and Yemenite Jews (0.849/0.151). Thus, the CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) variants were rare in the Japanese population, and showed different frequencies in the four Jewish ethnic groups examined...
Response to Sykiotis and Papavassiliou: Professional education in molecular medicine--pharmacogenetics firstJeantine E Lunshof
Trends Mol Med 11:485-6. 2005
